Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

In previously reported positive topline results from pivotal Phase 2/3 clinical trial in December 2019, vazegepant achieved statistical superiority to placebo on the co-primary regulatory endpoints of pain freedom and freedom from most bothersome symptom a... Biopharmaceuticals, FDA Biohaven Pharmaceutical, vazegepant, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news